Neoadjuvant PD-1 Monoclonal Antibody Plus Cisplatin-based... | NCT04672317

Status Module

Description Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Neoadjuvant arm	Experimental	Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy. Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible. Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy	Drug: Immunotherapy combined with chemotherapy

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Immunotherapy combined with chemotherapy	Drug	Patients will receive 2-4 cycles of Tislelizumab (200mg per cycle) in combination with cisplatin-based chemotherapy before radical nephroureterectomy and lymphadenectomy. Drug: Tislelizumab 200 mg per cycle, IV on day 14 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy Other Names: • anti-PD-1 monoclonal antibody Drug: Cisplatin 70mg/m2 IV on day 2of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy. Dose fractionation is permissible. Drug: Gemcitabine 1000mg/m2 IV on day 1 and Day 8 of every 3-week cycle, for 2-4 cycles prior to radical nephroureterectomy and lymphadenectomy

Measure	Description	Time Frame
Pathological complete response rate	the absence of visible lesion of carcinoma (ypT0/Tis) and the absence of microscopic lymph node metastases (ypN0) on the final surgical specimen	30 days after surgery

Measure	Description	Time Frame
Pathologic response rate	The rate of patients that reach pathological downstaging at the time of nephroureterectomy.	30 days after surgery

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

1. Patients that are identified as locally advanced upper urinary tract urothelial carcinoma by ureteroscopic biopsy and imaging diagnosis and are determined as appropriate candidates for radical nephrectomy by an attending urologist; 2. Patients who have a clinical stage of T3-T4, any N, M0 or any T, N1-2, M0; 3. ECOG performance status of 0 to 2; 4. Adequate organ function defined by study-specified laboratory tests;
1. Hemoglobin ≥90 g/L;
2. Hematological Absolute neutrophil count (ANC) ≥1.5×109 /L;
3. Platelets ≥100×109 /L 5. No functional organic disease: T-BIL≤1.5×upper limit of normal (ULN); ALT and AST≤2.5×ULN；eGFR ≥ 60ml/min (MdRD) 6. Agree to comply with scheduled visits, treatment plans, lab tests and any other required study procedures;

Exclusion Criteria:

Patients who has received prior therapy of an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody;
Patients who are allergic to monoclonal antibodies or any of its excipients;
Patients who have received other anti-tumor treatment (e. g., Steroid therapy, immunotherapy) within 4 weeks or enrolled in other clinical trials;
Patients who are pregnant or breastfeeding, or expecting to conceive;
Patients who have a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies);
Patients who have known active Hepatitis B or Hepatitis C;
Patients who have active autoimmune disease that has required systemic treatment in the past 2 years;
Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment;
Patients who have received prior radiation therapy to the bladder;
Patients who have bladder cancer;
Patients who have received allogeneic hematopoietic stem cell transplantation or solid organ transplantation;
Patients who have a history of substance abuse or with a history of mental disorders;
Patients who had other malignant tumors in the past five years that have not recovered except for curable tumors that have been cured including basal or squamous skin cancer, localized carcinoma in situ of the cervix or the breast or low-risk prostate cancer, etc;Patients who have active tuberculosis;
Patients who have other serious and uncontrollable accompanying diseases that may affect compliance or interfere with the interpretation of results including active opportunistic infections or advanced (severe) infections, uncontrollable diabetes, cardiovascular disease (grade III or IV heart failure defined by the New York Heart Association classification, II degree atrioventricular block and above, myocardial infarction in the past 6 months, unstable arrhythmia or instability angina, cerebral infarction within 3 months, etc.) or lung disease (interstitial pneumonia, history of obstructive lung disease and symptomatic bronchospasm);
Patients who have a large amount of pleural fluid or ascites with clinical symptoms or requiring symptomatic treatment.